Pharma BD Deal Intelligence
Watson Pharmaceuticals (Actavis) bought Uteron Pharma for $150M upfront plus up to $155M in milestones, but gutted the R&D team within 18 months and let the prize asset—the estetrol contraceptive Estelle—slip away to Mithra Pharmaceuticals, which won FDA approval as Nextstellis in 2021 while Actavis captured none of that value.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Watson buys Belgium-based Uteron for $150M up front plus $155M in milestones, adding hormonal IUD, novel OC, and an IVF diagnostic to its women's health…
Coincident with the Uteron close, Watson announced its corporate rebrand to Actavis as it absorbed the prior Actavis Group acquisition.
The acquisition strengthens Watson's originator pipeline within Global Brands and capitalizes on growing women's health franchise after Actavis Switzerland…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Watson acquired Belgium-based Uteron Pharma for $150M cash upfront + up to $155M milestones; expanded Global Brands women's health pipeline (contraception, infertility, IUDs).
Assessment window: 5yr post-close.
Contraception and infertility together represent the core of women's health pharmaceutical demand. Long-acting reversible contraception (LARC), particularly hormonal IUDs releasing levonorgestrel, has grown to dominate prescription contraception due to >99% efficacy and 5-8 year duration. In parallel, IVF clinics seek non-invasive biomarkers to improve oocyte selection and pregnancy rates.
At deal time, Bayer's Mirena (52 mg levonorgestrel IUD, approved 2000) was the dominant hormonal IUD with multi-hundred-million-dollar US sales, joined by Bayer's Skyla (lower-dose, approved Jan 2013). Teva's ParaGard copper IUD was the only non-hormonal alternative. Watson's Levosert was a direct generic-equivalent challenger to Mirena pursuing both contraception and heavy-menstrual-bleeding indications, with EU approval pending and US Phase 3 ongoing; patent runway to 2031 made it strategically valuable. The novel oral contraceptive (later Estelle/E4/Nextstellis, approved 2021) added a differentiated estetrol-based OC with potential better hepatic-metabolism profile. Diafert addressed a near-empty IVF biomarker space by measuring G-CSF in follicular fluid to grade oocyte quality. The Uteron deal followed Watson's October 2012 close of Actavis Group, building Watson's Global Brands franchise as it rebranded to Actavis. Watson/Actavis later sold Levosert rights to Pernix and the women's health portfolio was largely divested when Allergan acquired Actavis (2015). Levosert ultimately reached US market in 2016.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA (this deal) | 2013 | $305M | 16 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
← Browse all deals · How we score deals
More: 2013 deals · Watson Pharmaceuticals (Actavis Inc.) deals · Women's Health deals